1228947-14-5

Basic information

• Product Name: trans-4-Morpholinocyclohexanol
• Synonyms: trans-4-Morpholinocyclohexanol;trans-4-(4-Morpholinyl)cyclohexanol;trans-4-Morpholin-4-yl-cyclohexanol;EOS-60732
• CAS NO: 1228947-14-5
• Molecular Formula: C₁₀H₁₉NO₂
• Molecular Weight: 185.26336
• Mol File: 1228947-14-5.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: trans-4-Morpholinocyclohexanol(CAS DataBase Reference)
• NIST Chemistry Reference: trans-4-Morpholinocyclohexanol(1228947-14-5)
• EPA Substance Registry System: trans-4-Morpholinocyclohexanol(1228947-14-5)

Safety Data

• Hazardous Substances Data: 1228947-14-5(Hazardous Substances Data)

Usage

Description

Trans-4-Morpholinocyclohexanol is an organic compound that features a cyclohexanol structure with a morpholino group attached trans to the hydroxyl group. It is a versatile reagent in the field of organic synthesis and has potential applications in the pharmaceutical industry due to its ability to form various derivatives with biological activities.

Uses

Used in Pharmaceutical Industry:
Trans-4-Morpholinocyclohexanol is used as a reagent for the preparation of quinazoline and quinoline derivatives. These derivatives have been found to act as interleukin-1 receptor-associated kinases (IRAK) inhibitors, which play a crucial role in the regulation of inflammatory responses. By inhibiting IRAK, these derivatives can potentially be used in the development of treatments for various inflammatory diseases and conditions.

Upstream product

• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 
• 56239-26-0 (1s,4s)-4-aminocyclohexan-1-ol hydrochloride 
• 27489-62-9 trans-4-hydroxycyclohexylamine 

Downstream Products

• 1447957-41-6 C₂₄H₃₃N₃O₄S 
• 1447957-42-7 C₃₂H₄₆N₄O₅S 
• 1447952-51-3 12,12-dimethyl-3-[[4-(morpholin-4-yl)cyclohexyl]oxy]-11-oxa-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1⁽⁹⁾,2⁽⁷⁾,3,5-tetraene 
• 1388894-14-1 (3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2.6]]dodeca-1⁽¹²⁾,2⁽⁶⁾,8,10-tetraene 
• 1388894-17-4 2-((R)-4-(((1r,4r)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)acetamide 

Relevant articles and documents

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.